Overview

Safety And Efficacy Study Of Sunitinib Malate In Chinese Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor

Status:
Completed

Trial end date:
2014-10-01

Target enrollment:

Participant gender:

Summary

To investigate safety and efficacy of single agent sunitinib malate in Chinese Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor.

Phase:

Phase 4

Details

Lead Sponsor:

Pfizer

Treatments:

Imatinib Mesylate
Sunitinib